52025-36-2

Basic information

• Product Name: 6-(PROPAN-2-YLOXY)PYRIDIN-3-AMINE
• Synonyms: 6-isopropoxypyridin-3-amine;3-Pyridinamine, 6-(1-methylethoxy)-;6-(PROPAN-2-YLOXY)PYRIDIN-3-AMINE
• CAS NO: 52025-36-2
• Molecular Formula: C8H12N2O
• Molecular Weight: 152.19368
• Mol File: 52025-36-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(PROPAN-2-YLOXY)PYRIDIN-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(PROPAN-2-YLOXY)PYRIDIN-3-AMINE(52025-36-2)
• EPA Substance Registry System: 6-(PROPAN-2-YLOXY)PYRIDIN-3-AMINE(52025-36-2)

Safety Data

• Hazardous Substances Data: 52025-36-2(Hazardous Substances Data)

Usage

General Description

6-(Propan-2-yloxy)pyridin-3-amine is a chemical compound with the molecular formula C9H13N3O. It is a derivative of pyridine and contains a propyl group attached to the oxygen atom. 6-(PROPAN-2-YLOXY)PYRIDIN-3-AMINE has potential applications in pharmaceutical and medicinal chemistry, as it may exhibit biological activity due to its structural features. It is important to handle this chemical with care and follow proper safety protocols when working with it in the laboratory. Additionally, further research and testing may be necessary to fully understand its properties and potential uses.

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 24903-85-3 2-isopropoxy-5-nitropyridine 

Relevant articles and documents

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

HETEROARYL SULFONAMIDES AND CCR2

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.